Loading insider details...
Beta
Latest Form 4 (Oct 16, 2026): Exercise/Conversion of 19,333 AKTX shares, $7.73.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 16, 2026 | Akari Therapeutics Plc (AKTX) | Exercise/Conversion | 19,333 | $7.73 |
| Oct 1, 2026 | Akari Therapeutics Plc (AKTX) | Grant/Award | 6,430 | $62.5K |
| Jun 26, 2026 | Akari Therapeutics Plc (AKTX) | Grant/Award | 5,500 | n/a |
| Dec 19, 2025 | Akari Therapeutics Plc (AKTX) | Purchase | 309,328 | n/a |
| Aug 29, 2025 | Akari Therapeutics Plc (AKTX) | Purchase | 10,000 | $9.4K |
| Jun 25, 2025 | Akari Therapeutics Plc (AKTX) | Purchase | 943 | $1.1K |
| Jun 24, 2025 | Akari Therapeutics Plc (AKTX) | Purchase | 10,000 | $12.0K |
| Jun 20, 2025 | Akari Therapeutics Plc (AKTX) | Purchase | 15,000 | $18.0K |
| Jun 16, 2025 | Akari Therapeutics Plc (AKTX) | Grant/Award | 20,000 | $24.6K |
| Jun 12, 2025 | Akari Therapeutics Plc (AKTX) | Grant/Award | 20,000 | $25.4K |